Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;100(3):702-704.
doi: 10.1016/j.kint.2021.06.025. Epub 2021 Jun 30.

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis

Didier Ducloux  1 , Mathilde Colladant  2 , Melchior Chabannes  2 , Maria Yannaraki  2 , Cécile Courivaud  2
Affiliations

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis

Didier Ducloux et al. Kidney Int. 2021 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Antibody titers (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] immunoassay, which Abbott designed to detect IgG antibodies to the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2) before vaccine and after 2 and 3 doses of BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine. AU, arbitrary unit; S1, serology 1 = before vaccine; S2, serology 2 = after 2 doses; S3, serology 3 = after the third dose.
Figure 2
Figure 2
Receiver operating characteristic curve illustrating the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology after 2 doses of BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine to predict the increase in antibody titers after a third dose. Data in parentheses are interquartile range. AUC, area under the curve.
Figure 3
Figure 3
Individual variations in antibody titers (severe acute respiratory syndrome coronavirus 2 [SARS-Cov-2] immunoassay, which Abbott designed to detect IgG antibodies to the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2) during the vaccine scheme. AU, arbitrary unit.
See this image and copyright information in PMC

References

    1. Hsu C.M., Weiner D.E. COVID-19 in dialysis patients: outlasting and outsmarting a pandemic. Kidney Int. 2020;98:1402–1404. - PMC - PubMed
    1. Litjens N.H., Huisman M., van den Dorpel M., Betjes M.G. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol. 2008;19:1483–1490. - PMC - PubMed
    1. Jahn M., Korth J., Dorsch O. Humoral response to SARS-CoV-2-vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis. Vaccines (Basel) 2021;9:360. - PMC - PubMed
    1. Frantzen L, Cavaille G, Thibeaut S, El-Haik Y. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a hemodialysis cohort [e-pub ahead of print]. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab165. Accessed July 13, 2021. - DOI - PMC - PubMed
    1. Lacson E, Argyropoulos CP, Manley HJ, et al. Immunogenicity of SARS-CoV-2 vaccine in dialysis [preprint]. medRxiv. https://doi.org/10.1101/2021.04.08.21254779. Accessed July 13, 2021. - DOI - PMC - PubMed